Showing results (811-820 of 1,169) with videos related to
Sort By:
Pageof 117
Frontiers in Public Health|August 29, 2022
Quantifying the primary and secondary effects of antimicrobial resistance on surgery patients: Methods and data sources for empirical estimation in EnglandNichola R Naylor, Stephanie Evans, Koen B Pouwels, et al.Plos Medicine|November 4, 2025
Combining demographic shifts with age-based resistance prevalence to estimate future antimicrobial resistance burden in Europe and implications for targets: A modelling studyNaomi R Waterlow, Clare I R Chandler, Ben S Cooper, et al.Ecology|October 24, 2020
A multiscale framework for disentangling the roles of evenness, density, and aggregation on diversity gradientsDaniel J McGlinn, Thore Engel, Shane A Blowes, et al.Journal of Cell Science|April 20, 2018
Tissue stiffening promotes keratinocyte proliferation through activation of epidermal growth factor signalingFiona N Kenny, Zoe Drymoussi, Robin Delaine-Smith, et al.Molecular Immunology|November 1, 1995
The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regionsD M Knight, C Wagner, R Jordan, et al.Journal of Neurotrauma|May 6, 2009
Axon regeneration through scaffold into distal spinal cord after transectionBing Kun Chen, Andrew M Knight, Godard C W de Ruiter, et al.Vaccine|November 7, 2016
The TB vaccine H56+IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisionsSophie J Rhodes, Andrea Zelmer, Gwenan M Knight, et al.European Journal of Human Genetics : EJHG|March 7, 2008
Homozygosity mapping in a family presenting with schizophrenia, epilepsy and hearing impairmentHelen M Knight, Alan Maclean, Muhammad Irfan, et al.Rheumatology (Oxford, England)|February 1, 2007
The overall status in rheumatoid arthritis (OSRA) measure--further evidence to support its use in clinical practiceM J Harrison, A Hassell, P T Dawes, et al.Plos One|December 31, 2015
The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South AfricaGwenan M Knight, Gabriela B Gomez, Peter J Dodd, et al.Pageof 117